Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS
Status
Hovedstatus
Detaljstatus
I kraft info EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
Patentnummer NO/EP2849758
Europeisk (EP) publiserings nummer EP2849758
EP levert
EP søknadsnummer 13791356.2
EP meddelt
Prioritet 2012.05.14, US 201261646538 P, .... se mer/flere nedenfor
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Antecip Bioventures II LLC (US)
Oppfinner TABUTEAU, Herriot (US)
Fullmektig BRYN AARFLOT AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

T3

Beskrivelse

PAULO, pages 71 - 73, XP055176375, DATABASE PUBMED [Online] September 2004 XP055189738 & ROBINSON J.N. ET AL.: 'Efficacy ofpamidronate in complex regional pain syndrome type I' PAIN MED. vol.5, no.3, September 2004, pages 276 - 80, DATABASE PUBMED [Online] November 2004 XP055189741 Database accession no.15529370 & MANICOURT D.H. ET AL.: 'Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity' ARTHRITIS RHEUM. vol.50, no.11, November 2004, pages 3690 - 7, DATABASE PUBMED [Online] October 2008 XP055189746 Database accession no.18806533 & BREUER B. ET AL.: 'An open-label pilot trial ofibandronate for complex regional pain syndrome' CLIN J PAIN. vol.24, no.8, October 2008, pages 685 - 9, DATABASE PUBMED [Online] 04 August 2011 XP021106089 Database accession no.

21816057 & ABE Y. ET AL.: 'Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series' J MED CASE REP. vol.5, 04 August 2011, page 349, DATABASE PUBMED [Online] April 2005 XP027666044 Database accession no.15833263 & CHAUVINEAU V ET AL.: 'What is the place of diphosphonates in the treatment of complex regional pain syndrome I?' ANN READAPT MED PHYS. vol.48, no.3, April 2005, pages 150 - 7, DATABASE PUBMED [Online] 04 October 2000 XP055189751 Database accession no.11114855 & OURA S. ET AL.: 'Bisphosphonate therapy for bone metastases from breast cancer: clinical results and a new therapeutic approach' BREAST CANCER. vol.7, no.4, 04 October 2000, pages 307 - 10, DATABASE PUBMED [Online] 11718191 October 2001 XP055189755 Database accession no.

11718191 & HADJIPAVLOU A.G. ET AL.: 'Paget's disease of the spine and its management' EUR SPINE J. vol.10, no.5, October 2001, pages 370 - 84, DATABASE PUBMED [Online] November 2003 XP055189756 Database accession no.14623059 & EEKHOFF M.E. ET AL.: 'Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy' BONE vol.33, no.5, November 2003, pages 831 - 8, DATABASE PUBMED [Online] June 2003 Database accession no.12784404 & MATSUO A. ET AL.: 'Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis' J RHEUMATOL. vol.30, no.6, June 2003, pages 1280 -90, XP008176425, DATABASE PUBMED [Online] July 1998 Database accession no.9679211 & GOA K.L. ET ET AL.: 'Risedronate' DRUGS AGING. vol.13, no.1, July 1998, pages 83 - 91, XP008176426, DATABASE PUBMED [Online] August 1992 XP055191286 Database accession no.1642662 & REGINSTER J.Y. ET AL.: 'Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study' ARTHRITIS RHEUM. vol.35, no.8, August 1992, pages 967 - 74, XP055191191, DATABASE PUBMED [Online] October 2003 'EFFICACY OF DISODIUM-CLODRONATE IN THE MANAGEMENT OF JOINT PAIN IN RHEUMATOID ARTHRITIS. SIX MONTHS OPEN STUDY.', XP055191199 Retrieved from NCBI Database accession no.14973430 & ROVETTA G. ET AL.: 'Efficacy of disodium-clodronate in the management of joint pain in rheumatoid arthritis. Six months open study' MINERVA MED. vol.94, no.5, October 2003, pages 353 - 7, XP009130385, LASLETT LAURA LOUISE ET AL: "Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial.", ANNALS OF THE RHEUMATIC DISEASES AUG 2012, vol.71, no.8, August 2012 (2012-08), pages 1322-1328, XP008180591, ISSN: 1468-2060, POLASCIK THOMAS J ET AL: "Zoledronic acid in the management of metastatic bone disease.", THERAPEUTICS AND CLINICAL RISK MANAGEMENT FEB 2008, vol. 4, no.1, February 2008 (2008-02), pages 261-268, XP055317727, ISSN: 1176-6336, AMANAT NEGIN ET AL: "Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.", JOURNAL OF BONE AND MINERAL RESEARCH : THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH JUN 2007, vol.22, no.6, June 2007 (2007-06), pages 867-876, XP055317002, ISSN: 0884-0431, DATABASE PUBMED [Online] September 2008 XP055189761 Database accession no.18831886 & FUJITA T. ET AL.: 'Analgesic and chondroprotective effects ofrisedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine' J INT MED RES. vol.

36, no.5, September 2008, pages 932 - 41, WO-A2-02/43738

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Krav

Patentkrav1. Zoledronsyre for anvendelse ved behandling av komplekst regionalt smertesyndrom hos et pattedyr, hvor en oral doseringsform inneholdende zoledronsyre administreres i en total månedlig dose av zoledronsyre som er omtrent 100 mg/m2 til omtrent 600 mg/m2 basert på pattedyrets kroppsoverflateareal.2. Zoledronsyre for anvendelse ifølge krav 1, hvor den månedlige dosen kan gis som to eller flere individuelle doser administrert i løpet av måneden.3. Zoledronsyre for anvendelse ifølge krav 1 eller 2, hvor pattedyret er et menneske og den totale månedlige dosen av zoledronsyre er fra 100 mg/m2 til 200 mg/m2.4. Zoledronsyre for anvendelse ifølge krav 3, hvor den totale månedlige dosen administreres i 4 eller 5 ukentlige doser.5. Zoledronsyre for anvendelse ifølge krav 3, hvor den totale månedlige dosen administreres i 28 til 31 daglige doser.6. Zoledronsyre for anvendelse ifølge et hvilket som helst av de foregående krav, hvor pattedyret er et menneske som mottar en total ukentlig dose av zoledronsyre som er fra 10 mg til 300 mg.7. Zoledronsyre for anvendelse ifølge et hvilket som helst av de foregående krav, hvor zoledronsyren administreres som et salt av et dianion av zoledronsyre.
Hva betyr A1, B, B1, C osv? info
Innehaver i EP:
Antecip Bioventures II LLC
630 Fifth Avenue New York, NY 10111 US
260 Park Avenue South Apt. 7B New York, NY 10010 US
Fullmektig i Norge:
BRYN AARFLOT AS
Stortingsgata 8 0161 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 979993269
Din referanse: 130799 AFI
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
Green, Mark Charles
Murgitroyd & Company London Euston House 24 Eversholt Street London NW1 1AD GB

2012.05.14, US 201261646538 P

2012.05.15, US 201261647478 P

2012.06.01, US 201261654292 P

2012.06.01, US 201261654383 P

2012.06.05, US 201261655527 P

2012.06.05, US 201261655541 P

2013.02.07, US 201361762225 P

2013.02.14, US 201361764563 P

2013.02.21, US 201361767647 P

2013.02.21, US 201361767676 P

2013.03.20, US 201361803721 P

AMANAT NEGIN ET AL: "Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.", JOURNAL OF BONE AND MINERAL RESEARCH : THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH JUN 2007, vol. 22, no. 6, June 2007 (2007-06), pages 867-876, XP055317002, ISSN: 0884-0431 (B1)

WO-A2-02/43738 (B1)

CASTRO A.P.C. ET AL.: 'Zoledronic acid to treat complex regional pain syndrome type I in adult. Case report.' REV DOR. SATILDE vol. 12, no. 1, January 2011, O PAULO, pages 71 - 73, XP055176375 (B1)

CASTRO A.P.C. ET AL: "Zoledronic acid to treat complex regional pain syndrome type I in adult. Case report*", REV DOR. SATILDE, vol. 12, no. 1, January 2011 (2011-01), XP055176375, (B1)

Catherine McHugh, Thomas Leonard, Bozena Adamczyk, and Angela Walsh: "MER-101 tablets: A pilot bioavailability study of a novel oral formulation of zoledronic acid. (Abstract B194)", Molecular Cancer Therapeutics, vol. 6 November 2007 (2007-11), XP002750821, Retrieved from the Internet: URL:http://mct.aacrjournals.org/content/6/ 11_Supplement/B194.short [retrieved on 2015-11-11] (B1)

DATABASE PUBMED [Online] 04 August 2011 XP021106089 Database accession no. 21816057 & ABE Y. ET AL.: 'Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series' J MED CASE REP. vol. 5, 04 August 2011, page 349 (B1)

DATABASE PUBMED [Online] 04 October 2000 XP055189751 Database accession no. 11114855 & OURA S. ET AL.: 'Bisphosphonate therapy for bone metastases from breast cancer: clinical results and a new therapeutic approach' BREAST CANCER. vol. 7, no. 4, 04 October 2000, pages 307 - 10 (B1)

DATABASE PUBMED [Online] 11718191 October 2001 XP055189755 Database accession no. 11718191 & HADJIPAVLOU A.G. ET AL.: 'Paget's disease of the spine and its management' EUR SPINE J. vol. 10, no. 5, October 2001, pages 370 - 84 (B1)

DATABASE PUBMED [Online] April 2005 XP027666044 Database accession no. 15833263 & CHAUVINEAU V ET AL.: 'What is the place of diphosphonates in the treatment of complex regional pain syndrome I?' ANN READAPT MED PHYS. vol. 48, no. 3, April 2005, pages 150 - 7 (B1)

DATABASE PUBMED [Online] August 1992 XP055191286 Database accession no. 1642662 & REGINSTER J.Y. ET AL.: 'Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study' ARTHRITIS RHEUM. vol. 35, no. 8, August 1992, pages 967 - 74, XP055191191 (B1)

DATABASE PUBMED [Online] July 1998 Database accession no. 9679211 & GOA K.L. ET ET AL.: 'Risedronate' DRUGS AGING. vol. 13, no. 1, July 1998, pages 83 - 91, XP008176426 (B1)

DATABASE PUBMED [Online] June 2003 Database accession no. 12784404 & MATSUO A. ET AL.: 'Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis' J RHEUMATOL. vol. 30, no. 6, June 2003, pages 1280 - 90, XP008176425 (B1)

DATABASE PUBMED [Online] November 2003 XP055189756 Database accession no. 14623059 & EEKHOFF M.E. ET AL.: 'Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy' BONE vol. 33, no. 5, November 2003, pages 831 - 8 (B1)

DATABASE PUBMED [Online] November 2004 XP055189741 Database accession no. 15529370 & MANICOURT D.H. ET AL.: 'Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity' ARTHRITIS RHEUM. vol. 50, no. 11, November 2004, pages 3690 - 7 (B1)

DATABASE PUBMED [Online] October 2003 'EFFICACY OF DISODIUM-CLODRONATE IN THE MANAGEMENT OF JOINT PAIN IN RHEUMATOID ARTHRITIS. SIX MONTHS OPEN STUDY.', XP055191199 Retrieved from NCBI Database accession no. 14973430 & ROVETTA G. ET AL.: 'Efficacy of disodium-clodronate in the management of joint pain in rheumatoid arthritis. Six months open study' MINERVA MED. vol. 94, no. 5, October 2003, pages 353 - 7, XP009130385 (B1)

DATABASE PUBMED [Online] October 2008 XP055189746 Database accession no. 18806533 & BREUER B. ET AL.: 'An open-label pilot trial ofibandronate for complex regional pain syndrome' CLIN J PAIN. vol. 24, no. 8, October 2008, pages 685 - 9 (B1)

DATABASE PUBMED [Online] September 2004 XP055189738 & ROBINSON J.N. ET AL.: 'Efficacy ofpamidronate in complex regional pain syndrome type I' PAIN MED. vol. 5, no. 3, September 2004, pages 276 - 80 (B1)

DATABASE PUBMED [Online] September 2008 XP055189761 Database accession no. 18831886 & FUJITA T. ET AL.: 'Analgesic and chondroprotective effects ofrisedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine' J INT MED RES. vol. 36, no. 5, September 2008, pages 932 - 41 (B1)

JARRETT STEPHEN J ET AL: "Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.", ARTHRITIS AND RHEUMATISM MAY 2006, vol. 54, no. 5, May 2006 (2006-05), pages 1410-1414, XP055317004, ISSN: 0004-3591 (B1)

LASLETT LAURA LOUISE ET AL: "Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial.", ANNALS OF THE RHEUMATIC DISEASES AUG 2012, vol. 71, no. 8, August 2012 (2012-08), pages 1322-1328, XP008180591, ISSN: 1468-2060 (B1)

POLASCIK THOMAS J ET AL: "Zoledronic acid in the management of metastatic bone disease.", THERAPEUTICS AND CLINICAL RISK MANAGEMENT FEB 2008, vol. 4, no. 1, February 2008 (2008-02), pages 261-268, XP055317727, ISSN: 1176-6336 (B1)

US-A1- 2004 087 551 (B1)

US-A1- 2007 134 319 (B1)

US-A1- 2010 215 743 (B1)

US-A1- 2011 098 252 (B1)

US-B2- 7 704 977 (B1)

WO-A1-2004/035061 (B1)

WO-A1-2011/014781 (B1)

Anonymous: "Equivalent Surface Area Dosage Conversion Factors", NCIatFrederick , April 2015 (2015-04), XP002750822, Retrieved from the Internet: URL:https://ncifrederick.cancer.gov/lasp/a cuc/frederick/Media/Documents/ACUC42.pdf [retrieved on 2015-11-10] (B1)

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210)
05-01 Via Altinn-sending EP Registreringsbrev (3210)
Innkommende, AR259611935 Korrespondanse (Hovedbrev inn)
04-01 Korrespondanse (Hovedbrev inn) Korrespondanse (Hovedbrev inn)
04-02 Fullmakt Fullmakt
Utgående EP defect letter
03-01 Via Altinn-sending EP defect letter
Innkommende, AR255444397 Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 EP oversettelse EP krav
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO

Til betaling:

Beskrivelse Forfallsdato Beløp Status
Årsavgift expand_less Ikke betalt
Årsavgift 13. avg. år (EP) 5460,0 Totalbeløp 5460,0   Gå til betaling

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 12. avg. år (EP) 2024.04.19 5010 ANAQUA SERVICES Betalt og godkjent
Årsavgift 11. avg. år (EP) 2023.04.20 3500 ANAQUA SERVICES Betalt og godkjent
Årsavgift 10. avg. år (EP) 2022.04.22 3200 1/ANAQUA SERVICES Betalt og godkjent
Årsavgift 9. avg. år (EP) 2021.05.11 2850 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 8. avg. år (EP) 2020.05.11 2550 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 7. avg. år (EP) 2019.05.09 2200 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 6. avg. år (EP) 2018.05.09 2000 CPA GLOBAL LIMITED Betalt og godkjent
31806689 expand_more 2018.05.02 5500 BRYN AARFLOT AS Betalt
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Allment tilgjengelig patentsøknad
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 27.04.2025 09:03:56